3 / 17
Page 34
Notes:
conferenceseries
.com
June 26-27, 2017 San Diego, USA
13
th
International conference on
Pathology and Molecular Diagnosis
Volume 7, Issue 2 (Suppl)
J Clin Exp Pathol, an open access journal
ISSN:2161-0681
Pathology and Molecular Diagnosis 2017
June 26-27, 2017
Diagnostic challenges in lung neuroendocrine tumors
Mark Podberezin
University of Saskatchewan, Canada
N
euroendocrine tumors (NET) of the lung constitute approximately 15% of all lung tumors, with small cell lung cancer
(SCLC) accounting for 15% of invasive cancers. Many of those tumors have radiological and clinical presentation which
is different from other pulmonary malignancies. In most cases, diagnosis could be established by core needle biopsy and, not
uncommonly, SCLC is detected by endoscopic bronchial ultrasound fine needle aspiration (EBUS-FNA). Spectrum of lung
NETs includes typical carcinoid (TC), atypical carcinoid (AC), SCLC and large cell neuroendocrine carcinoma (LCNEC).
Morphological criteria, separating low grade from high grade NETs, include cellular atypia, mitotic rate, and presence or
absence of necrosis. The question, which has been yet unanswered and which is addressed in the presentation, is whether the
above NETs represent continuum from low to high grade tumors or they are biologically different. One of the major diagnostic
challenges in pulmonary NETs is their grading on core needle biopsies (CNB). It has been shown that morphological features
of NET, when diagnosed by CNB, could be significantly different from the ones on same tumor upon subsequent surgical
resection. This could be partially due to marked crush and processing artifact which markedly affect evaluation of mitotic
rate. Measurement of proliferative rate by immunohistochemical stain for Ki67 has been approved for grading of NET in
the gastrointestinal tract, but is not universally accepted in pulmonary NET. However, it can be very helpful in evaluation of
CNB with marked cautery and crush artifact. In addition, CNBs may not be representative of the entire lesion and can lead to
diagnostic pitfalls which will be discussed in the presentation.
Biography
Mark Podberezin has completed his Medical School Degree (MD) and subsequent Clinical Hematology/Oncology training and PhD in Russia. Later, he did his
Residency in Anatomic and Clinical Pathology at University of Illinois at Chicago and Hematopathology Fellowship at Texas Methodist Hospital in Houston. He is
an Anatomic Pathologist (with special interest in Lung Pathology) and Hematopathologist at Royal University Hospital, University of Saskatchewan, Canada. He
published 14 papers and presented at national, as well as international meetings.
mark.podberezin@saskatoonhealthregion.caMark Podberezin, J Clin Exp Pathol 2017, 7:2 (Suppl)
DOI: 10.4172/2161-0681-C1-034